Compare Natera Inc. Common Stock (NTRA) vs Permian Resources Corporation Class A Common Stock (PR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Permian Resources Corporation Class A Common Stock — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Permian Resources Corporation Class A Common Stock trades at $24.13 (market cap $20.32B). The key difference: Natera Inc. Common Stock is far larger — about 2.8× Permian Resources Corporation Class A Common Stock's market cap, and Permian Resources Corporation Class A Common Stock pays a 2.6% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Permian Resources Corporation Class A Common Stock for 5 Days on average.
| NTRA | PR | |
|---|---|---|
Market Cap | $57.03B | $20.32B |
Volume | 1,131,157 | 10,979,775 |
Sector | Health | Energy |
52-Week High | $425.64 | $24.49 |
52-Week Low | $179.42 | $12.09 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $56.18B | $23.32B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Permian Resources (PR) trades at $24.26, up 3.68% on the day and near its 52-week high, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $5.07B revenue, 21.52% net income margin, and attractive valuation metrics including a P/E of 15.65 and EV/EBITDA of 5.83. Recent earnings show mixed results with Q2 2026 beating expectations by 59% while Q1 2026 missed estimates.
The outlook remains positive with 90% analyst buy ratings and $27.00 consensus price target representing 11% upside. Key opportunities include disciplined acquisition strategy and raised 2026 guidance, while risks involve oil price volatility and execution of capital spending plans. The stock offers growth potential but requires monitoring of quarterly execution consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Permian Resources Corporation Class A Common Stock
Permian Resources explores for and produces oil and natural gas in the Permian Basin. Its operations are concentrated in the Delaware Basin of West Texas and New Mexico.
Read more on PR →
